Osteopontin dysregulation and lytic bone lesions in multiple myeloma

Davide F. Robbiani, Kaity Colon, Sarah Ely, Scott Ely, Marta Chesi, P. Leif Bergsagel

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Osteopontin (OPN), a secreted phosphoprotein involved in immune regulation and bone homeostasis, is a major component of bone, the natural habitat of long-lived plasma cells and multiple myeloma (MM). We show that only some MM cell lines and primary patient samples express OPN at high levels. High OPN expression inversely correlates with bone disease. When we subdivide MM into molecular subtypes, OPN is significantly upregulated in patients with maf translocations, particularly in the fraction lacking bone disease. OPN is produced in osteolytic lesions: we propose that MM-derived OPN plays a critical role in bone disease by protecting bone from destruction.

Original languageEnglish (US)
Pages (from-to)16-20
Number of pages5
JournalHematological Oncology
Issue number1
StatePublished - Mar 1 2007


  • Bone disease
  • Maf
  • Molecular classification
  • Myeloma
  • Osteopontin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Osteopontin dysregulation and lytic bone lesions in multiple myeloma'. Together they form a unique fingerprint.

Cite this